Auris Medical Holding AG. Daily Stock Analysis

Daily Stock Analysis, EARS, Auris Medical Holding AG, priceseries

Auris Medical Holding AG. Daily Stock Analysis
Stock Information
Open
2.37
Close
2.39
High
2.47
Low
2.32
Previous Close
2.34
Daily Price Gain
0.05
YTD High
1592.00
YTD High Date
Jan 6, 2016
YTD Low
0.65
YTD Low Date
Mar 17, 2020
YTD Price Change
-1197.61
YTD Gain
-99.80%
52 Week High
6.25
52 Week High Date
Mar 9, 2021
52 Week Low
2.01
52 Week Low Date
Sep 20, 2021
52 Week Price Change
-1.03
52 Week Gain
-30.12%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 10. 2017
156.00
Mar 27. 2017
175.42
11 Trading Days
12.45%
Link
LONG
Sep 28. 2017
159.78
Oct 12. 2017
173.21
10 Trading Days
8.40%
Link
LONG
Aug 23. 2018
5.80
Aug 24. 2018
6.10
1 Trading Days
5.19%
Link
LONG
Oct 5. 2018
9.40
Oct 10. 2018
10.04
3 Trading Days
6.86%
Link
LONG
Oct 11. 2018
13.60
Oct 18. 2018
17.60
5 Trading Days
29.41%
Link
LONG
Dec 28. 2018
9.72
Dec 31. 2018
10.27
1 Trading Days
5.72%
Link
LONG
May 8. 2019
5.37
May 9. 2019
5.79
1 Trading Days
7.73%
Link
LONG
Aug 7. 2020
1.08
Aug 11. 2020
1.18
2 Trading Days
8.80%
Link
LONG
Nov 18. 2020
0.87
Dec 9. 2020
2.71
14 Trading Days
211.50%
Link
LONG
Dec 11. 2020
2.76
Dec 14. 2020
2.93
1 Trading Days
6.16%
Link
LONG
Feb 3. 2021
3.01
Feb 23. 2021
3.56
13 Trading Days
18.40%
Link
LONG
Mar 8. 2021
3.42
Mar 12. 2021
3.67
4 Trading Days
7.46%
Link
LONG
May 26. 2021
3.29
Jun 4. 2021
3.51
6 Trading Days
6.68%
Link
Company Information
Stock Symbol
EARS
Exchange
NasdaqGM
Company URL
http://www.aurismedical.com
Company Phone
41 (0)61 201 13 50
CEO
Thomas Meyer
Headquarters
-
Business Address
FALKNERSTRASSE 4, 4001 BASEL, SWITZERLAND 00000
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001601936
About

Auris Medical Holding AG engages in the research, development, and commercialization of pharmaceutical products for inner ear disorders. Its product portfolio targets to treat tinnitus, Menière's disease, and hearing loss. The company was founded by Thomas Meyer on April 1, 1998 and is headquartered in Zug, Switzerland.

Description

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading